Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989 Dec;35(3):367-72.
doi: 10.1016/0090-8258(89)90081-4.

Immunotherapy Using the Streptococcal Preparation OK-432 for the Treatment of Uterine Cervical Cancer. Cervical Cancer Immunotherapy Study Group

Affiliations
Clinical Trial

Immunotherapy Using the Streptococcal Preparation OK-432 for the Treatment of Uterine Cervical Cancer. Cervical Cancer Immunotherapy Study Group

K Noda et al. Gynecol Oncol. .

Abstract

The efficacy of immunotherapy using a streptococcal preparation, OK-432, was evaluated in each clinical stage of uterine cervical cancer. The 382 eligible patients were stratified by clinical stage and presence/absence of surgery. Within each stratum, patient's were randomly allocated to OK-432 treatment or to control treatment. OK-432 significantly inhibited recurrence in patients with stage II cervical cancer; the recurrence-free interval and survival time were remarkably prolonged in patients with stage II disease who underwent surgery. However, OK-432 did not significantly prolong these parameters in patients with stage III disease. Retrospective analyses revealed that in patients with or without lymph node metastases who underwent surgery, the recurrence-free interval and survival time were significantly prolonged by OK-432 treatment. These results indicate that OK-432 is an effective and useful postoperative immunotherapeutic agent for uterine cervical cancer.

Similar articles

See all similar articles

Publication types

MeSH terms

Feedback